UBS analyst David Low lowered the price target on ResMed (NYSE: RMD) to $300.00 (from $312.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE